The US Food and Drug Administration (FDA) suggested a "potential correlation" between dog breed and side effects from Pfizer's weight loss drug Slentrol, according to a health blog from the Wall Street Journal.
These preliminary findings are part of FDA's study of genetic data on dogs that have taken Slentrol, to determine if certain breeds are more susceptible to problems. The blog says Pfizer disagreed with FDA's results, saying the breeds most often associated with adverse side effects from Sentrol, including Labrador Retriever, Beagle, Golden Retriever, Dachshund, Pug and Chihuahua, are very common and some are predisposed to obesity. The company claims its side effects listed on the label are usually mild and do not seem to disproportionately affect specific breeds.
By Lindsay Beaton
As work continues on creating a new nutrition label that focuses on simplifying information for consumers, challenges remain.
By Tang Yu